Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020
Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD) announced it will unveil third quarter 2020 results on November 10, 2020, at 8:30 a.m. ET. A conference call will follow to discuss financial outcomes and corporate updates. The call is accessible via phone and webcast, with U.S. callers dialing +1-646-741-3167, and international callers using +44 (0) 2071 928338. Interested parties can also access the live audio webcast through the company’s website, where a replay will be available for 30 days post-call.
- Affimed is actively enrolling patients in clinical trials for innovative cancer therapies.
- The company is advancing its ROCK® platform for innate cell engagers aimed at treating specific cancer populations.
- None.
Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2020 results on Tuesday, November 10, 2020 and host a conference call at 8:30 a.m. ET to discuss financial results and corporate developments.
The conference call will be available via phone and webcast. To access the call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference conference ID 9847055 approximately 15 minutes prior to the call.
To access the live audio webcast of the conference call please visit the “Investors” section of the company’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on the Affimed website for 30 days after the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.
Investor Relations Contact
Alex Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel: +1 (917) 436-8102
FAQ
When will Affimed release its third quarter 2020 results?
What time is the conference call for Affimed's Q3 results?
How can I access the Affimed conference call?
Is there a webcast available for Affimed's Q3 results?
How long will the Q3 conference call replay be available?
